Zoetis (NYSE:ZTS) Issues FY 2026 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 6.850-7.000 for the period, compared to the consensus EPS estimate of 7.030. The company issued revenue guidance of $9.7 billion-$10.0 billion, compared to the consensus revenue estimate of $9.9 billion.

Zoetis Trading Down 5.2%

Shares of NYSE ZTS traded down $4.51 during mid-day trading on Friday, hitting $82.80. The company’s stock had a trading volume of 17,182,879 shares, compared to its average volume of 4,931,078. The stock has a market cap of $34.83 billion, a price-to-earnings ratio of 13.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis has a one year low of $81.10 and a one year high of $172.23. The company’s fifty day simple moving average is $118.49 and its 200-day simple moving average is $123.70.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 61.97%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis will post 7.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZTS has been the topic of several recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Bank of America increased their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. UBS Group cut their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday. Citigroup started coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target on the stock. Finally, Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average price target of $141.25.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: JPMorgan lowered its price target on Zoetis from $190 to $130, but kept an overweight rating, implying the stock still has meaningful upside from current levels. Benzinga report on JPMorgan target cut
• Neutral Sentiment: Some analysts remain constructive overall, with recent coverage still showing buy/overweight views and price targets well above the current share price, suggesting longer-term confidence despite near-term pressure.
• Negative Sentiment: Zoetis missed Q1 earnings and revenue estimates, which immediately hurt sentiment around the stock.
• Negative Sentiment: The company cut its FY2026 guidance after seeing weaker U.S. companion animal demand and pricing pressure, raising concerns that pet owners are spending less on veterinary care and premium products. Benzinga report on weak pet care demand
• Negative Sentiment: Media coverage described the earnings release as a sharp disappointment, with reports highlighting a steep selloff after investors reacted to the softer outlook.
• Negative Sentiment: Ademi LLP announced a securities fraud investigation into Zoetis, adding another overhang for shares as investors assess potential legal risk.

Institutional Trading of Zoetis

Several hedge funds have recently bought and sold shares of ZTS. FIL Ltd raised its holdings in Zoetis by 372.2% during the 4th quarter. FIL Ltd now owns 2,134,404 shares of the company’s stock worth $268,551,000 after buying an additional 1,682,384 shares during the period. Amundi raised its holdings in Zoetis by 51.2% during the 4th quarter. Amundi now owns 4,001,317 shares of the company’s stock worth $503,445,000 after buying an additional 1,354,581 shares during the period. Corient Private Wealth LLC raised its holdings in Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after buying an additional 1,191,840 shares during the period. Voloridge Investment Management LLC raised its holdings in Zoetis by 263.1% during the 4th quarter. Voloridge Investment Management LLC now owns 1,144,610 shares of the company’s stock worth $144,015,000 after buying an additional 829,415 shares during the period. Finally, Worldquant Millennium Advisors LLC raised its holdings in Zoetis by 737.9% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 912,477 shares of the company’s stock worth $142,301,000 after buying an additional 803,573 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.